Revolution Medicines, Inc. Common Stock
RVMDRevolution Medicines, Inc. (RVMD) is a biopharmaceutical company focused on developing targeted therapies for genetically driven cancers. The company specializes in designing innovative medicines aimed at specific genetic mutations involved in cancer progression, with an emphasis on solid tumors and hematologic malignancies.
Company News
Revolution Medicines, a pre-revenue biotech company developing targeted cancer treatments to replace chemotherapy, has surged 125% in 2026. The company's flagship drug Daraxonrasib received FDA Breakthrough Therapy designation and is undergoing accelerated review by the EMA. Billionaire Stanley Druckenmiller's Duquesne Family Office purchased 316...
A class action lawsuit has been filed against Erasca, Inc. alleging that the company and its executives made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims preclinical data was based on improper comparisons to Revolution Medicines and lacked reasonable basis. Following disclosure of a patent infringemen...
Faruqi & Faruqi, LLP is investigating securities fraud claims against Erasca, Inc. (NASDAQ: ERAS) for allegedly making false statements about its ERAS-0015 drug candidate based on improper comparisons to Revolution Medicines' compound. The company disclosed patent infringement allegations and a patient death in Phase 1 trials on April 27, 2026, c...
A class action lawsuit has been filed against Erasca, Inc. (NASDAQ: ERAS) on behalf of investors who purchased securities between January 14, 2025 and April 26, 2026. Shareholders allege that Erasca failed to disclose risks related to patent and trade secret violations regarding its ERAS-0015 drug candidate. The allegations emerged after Revoluti...
Three biotech companies—Moderna, Revolution Medicines, and Axsome Therapeutics—significantly outperformed the S&P 500 in the first half of 2026 with double- and triple-digit gains. While Moderna faces expected pullback despite flu vaccine approval prospects, and Revolution Medicines shows modest upside, Wall Street expects Axsome to climb ano...
